NZ629828A - Methods for the treatment of b cell-mediated inflammatory diseases - Google Patents
Methods for the treatment of b cell-mediated inflammatory diseasesInfo
- Publication number
- NZ629828A NZ629828A NZ629828A NZ62982813A NZ629828A NZ 629828 A NZ629828 A NZ 629828A NZ 629828 A NZ629828 A NZ 629828A NZ 62982813 A NZ62982813 A NZ 62982813A NZ 629828 A NZ629828 A NZ 629828A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cell
- treatment
- methods
- inflammatory diseases
- mediated inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261606049P | 2012-03-02 | 2012-03-02 | |
| PCT/US2013/028602 WO2013130959A1 (en) | 2012-03-02 | 2013-03-01 | Methods for the treatment of b cell-mediated inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ629828A true NZ629828A (en) | 2017-05-26 |
Family
ID=47844534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ629828A NZ629828A (en) | 2012-03-02 | 2013-03-01 | Methods for the treatment of b cell-mediated inflammatory diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9890213B2 (enExample) |
| EP (1) | EP2820045B1 (enExample) |
| JP (1) | JP6193275B2 (enExample) |
| KR (1) | KR102090969B1 (enExample) |
| CN (1) | CN104520323B (enExample) |
| AU (1) | AU2013225812B2 (enExample) |
| CA (1) | CA2865928C (enExample) |
| IN (1) | IN2014DN08199A (enExample) |
| NZ (1) | NZ629828A (enExample) |
| WO (1) | WO2013130959A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010129917A2 (en) | 2009-05-08 | 2010-11-11 | Vaccinex, Inc. | Anti-cd100 antibodies and methods for using the same |
| SG188285A1 (en) | 2010-09-02 | 2013-04-30 | Vaccinex Inc | Anti-cxcl13 antibodies and methods of using the same |
| AU2012322721B2 (en) | 2011-10-11 | 2016-05-05 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| CN105408355A (zh) * | 2013-01-31 | 2016-03-16 | 瓦克纳斯有限公司 | 用于提高免疫球蛋白a水平的方法 |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| US10577427B2 (en) | 2016-04-22 | 2020-03-03 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| BR112019001944A2 (pt) | 2016-08-02 | 2019-05-07 | Vaccinex, Inc. | métodos aperfeiçoados para produção de bibiliotecas de polinucleotídeo em células eucarióticas/vírus de vaccínia |
| SG11201901789WA (en) * | 2016-09-19 | 2019-03-28 | I Mab | Anti-gm-csf antibodies and uses thereof |
| US11554131B2 (en) * | 2018-05-31 | 2023-01-17 | Glycom A/S | Mixture of HMOs for treating autoimmune diseases |
| SG11202010499UA (en) * | 2018-09-18 | 2020-11-27 | I Mab Biopharma Us Ltd | Anti-cxcl13 antibodies for treating autoimmune diseases and cancer |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| WO1992008802A1 (en) | 1990-10-29 | 1992-05-29 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
| CA2108451A1 (en) | 1991-04-26 | 1992-10-27 | Beverley J. Randle | Novel antibodies, and methods for their use |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| PT627940E (pt) | 1992-03-05 | 2003-07-31 | Univ Texas | Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados |
| US6692920B1 (en) | 1994-12-07 | 2004-02-17 | Incyte Corporation | Antibodies to a chemokine expressed in inflamed adenoid |
| US5633149A (en) | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CN1190991A (zh) | 1995-06-05 | 1998-08-19 | 人类基因组科学公司 | 人类趋化因子β－11和人类趋化因子α－1 |
| AU4243097A (en) | 1996-09-10 | 1998-04-02 | Schering Corporation | Mammalian chemokines, related reagents |
| US6852508B1 (en) | 1997-02-28 | 2005-02-08 | Genetics Institute, Llc | Chemokine with amino-terminal modifications |
| US20030207346A1 (en) | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| AU2001250412A1 (en) | 2000-03-31 | 2001-10-08 | Ipf Pharmaceuticals Gmbh | Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| US7052676B2 (en) | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
| MXPA03004913A (es) | 2000-12-01 | 2003-09-05 | Schering Corp | Usos de genes de mamifero y reactivos relacionados. |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
| US7413866B2 (en) | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004045525A2 (en) | 2002-11-15 | 2004-06-03 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation. |
| WO2004045526A2 (en) | 2002-11-15 | 2004-06-03 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| JP2011516026A (ja) | 2002-11-26 | 2011-05-26 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| EA200501524A1 (ru) | 2003-03-28 | 2006-06-30 | Сентокор, Инк. | Антитела против амилоида, композиции, способы и применения |
| AU2005243730B2 (en) | 2004-04-12 | 2010-05-27 | Genvec, Inc. | Method of using adenoviral vectors to induce an immune response |
| CA2501422C (en) | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
| SI1674111T1 (sl) | 2004-07-09 | 2011-02-28 | Chugai Pharmaceutical Co Ltd | Protitelo proti glipikanu 3 |
| CN101120021A (zh) | 2004-12-31 | 2008-02-06 | 基因技术公司 | 结合br3的多肽及其用途 |
| ES2971647T3 (es) | 2005-04-15 | 2024-06-06 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
| WO2007064911A1 (en) | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| GB0607774D0 (en) * | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
| WO2007124414A2 (en) | 2006-04-21 | 2007-11-01 | Centocor, Inc. | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
| US20080227704A1 (en) | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
| US20080199481A1 (en) * | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
| MX2009010633A (es) | 2007-03-30 | 2009-11-26 | Centocor Ortho Biotech Inc | Antagonistas de la quimiocina interleucina-13 y su uso para el tratamiento de enfermedades inflamatorias. |
| WO2010053547A2 (en) * | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Cxcr5 receptor compounds |
| SG188285A1 (en) * | 2010-09-02 | 2013-04-30 | Vaccinex Inc | Anti-cxcl13 antibodies and methods of using the same |
| WO2013102123A2 (en) | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| CN105408355A (zh) | 2013-01-31 | 2016-03-16 | 瓦克纳斯有限公司 | 用于提高免疫球蛋白a水平的方法 |
| AU2013205589A1 (en) | 2013-03-08 | 2014-09-25 | Vaccinex, Inc. | Anti-CXCL13 antibodies and associated epitope sequences |
-
2013
- 2013-03-01 NZ NZ629828A patent/NZ629828A/en unknown
- 2013-03-01 KR KR1020147027747A patent/KR102090969B1/ko active Active
- 2013-03-01 CA CA2865928A patent/CA2865928C/en active Active
- 2013-03-01 EP EP13708639.3A patent/EP2820045B1/en active Active
- 2013-03-01 AU AU2013225812A patent/AU2013225812B2/en active Active
- 2013-03-01 IN IN8199DEN2014 patent/IN2014DN08199A/en unknown
- 2013-03-01 WO PCT/US2013/028602 patent/WO2013130959A1/en not_active Ceased
- 2013-03-01 CN CN201380022683.4A patent/CN104520323B/zh active Active
- 2013-03-01 JP JP2014560085A patent/JP6193275B2/ja active Active
- 2013-03-01 US US14/382,410 patent/US9890213B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104520323A (zh) | 2015-04-15 |
| JP2015509960A (ja) | 2015-04-02 |
| CA2865928A1 (en) | 2013-09-06 |
| JP6193275B2 (ja) | 2017-09-06 |
| KR102090969B1 (ko) | 2020-03-19 |
| CA2865928C (en) | 2021-02-16 |
| AU2013225812A1 (en) | 2014-09-25 |
| WO2013130959A1 (en) | 2013-09-06 |
| US9890213B2 (en) | 2018-02-13 |
| KR20140138830A (ko) | 2014-12-04 |
| EP2820045B1 (en) | 2018-08-22 |
| EP2820045A1 (en) | 2015-01-07 |
| IN2014DN08199A (enExample) | 2015-05-01 |
| AU2013225812B2 (en) | 2017-11-30 |
| CN104520323B (zh) | 2018-05-04 |
| US20150125467A1 (en) | 2015-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629828A (en) | Methods for the treatment of b cell-mediated inflammatory diseases | |
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| IN2015DN00450A (enExample) | ||
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| MX2016001186A (es) | Diagnostico y terapia de cancer que implica celulas madre cancerosas. | |
| PH12015502075B1 (en) | Treatment of cataplexy | |
| EA201491011A1 (ru) | Способы лечения с помощью ингибитора гамма-интерферона | |
| SG10201810615VA (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| BR112018003526A2 (pt) | métodos de tratamento de doenças inflamatórias | |
| EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
| MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
| PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
| MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
| EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
| EA202091676A1 (ru) | Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| MX2019013468A (es) | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. | |
| GB201109238D0 (en) | Antibodies | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
| MX2020001428A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| EA201690445A1 (ru) | Лечение рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 MAR 2020 BY FISHER ADAMS KELLY CALLINANS Effective date: 20170907 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2021 BY COMPUTER PACKAGES INC Effective date: 20200218 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2022 BY COMPUTER PACKAGES INC Effective date: 20210306 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2023 BY COMPUTER PACKAGES INC Effective date: 20220217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2024 BY COMPUTER PACKAGES INC Effective date: 20230217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2025 BY COMPUTER PACKAGES INC Effective date: 20240217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2026 BY COMPUTER PACKAGES INC Effective date: 20250217 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2027 BY COMPUTER PACKAGES INC Effective date: 20260217 |